Invion is in the process of undertaking a circa $4.5 million capital raising by way of a share placement as announced to the ASX on 2 June 2021, as part of its Co-Development Agreement and Exclusive Distribution and Licence Agreement between Invion and RMW Cho Group (RMW). Both parties will co-develop PhotosoftTM technology for potential applications in atherosclerosis and infectious diseases (including viral, bacterial, fungal and parasitic) (Indications). Invion will have exclusive rights to the technology for these diseases in Asia Pacific (which excludes the Middle East, Russia and the specified territories of China, Hong Kong, Macau and Taiwan) (Territory).
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)